FindTrial
Sign In

Effect of dexmedetomidine on the dose-response relationship of sufentanil inhibiting tracheal intubation response in patients undergoing coronary artery bypass grafting

Effect of dexmedetomidine on the dose-response relationship of sufentanil inhibiting tracheal intubation response in patients undergoing coronary artery bypass grafting

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020607
Enrollment
Unknown
Registered
2019-01-10
Start date
2019-01-02
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Group D:dexmedetomidine 0.5ug/kg
Group C:control saline

Sponsors

Yantai Yuhuangding Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
48 Years to 65 Years

Inclusion criteria

Inclusion criteria: Undergoing coronary artery bypass grafting, and to calculate the median effective dose of sufentanil in inhibiting tracheal intubation response (ED50); Patients undergoing elective coronary artery bypass grafting were 48-59 years of age, BMI 18.6-23.5 kg/m2, ASA II or III.

Exclusion criteria

Exclusion criteria: Severe cardiac membrane disease, arrhythmia, hepatic and renal insufficiency, combined with respiratory disease, central nervous system disease, metabolic disease, difficult airway, three-branch coronary artery disease, hypertension or diabetes history more than 10 years,EF 35%; With a history of heart surgery

Design outcomes

Primary

MeasureTime frame
Recording room (T1), before induction (T2), before cannulation (T3), cannulation immediately (T4), maximum (T5) HR, SBP and MAP within 5 minutes of intubation;—

Countries

China

Contacts

Public ContactHongzhong Ma

Yantai Yuhuangding Hospital

13305359686@163.com+86 13305359686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026